These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
735 related articles for article (PubMed ID: 23328811)
21. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244 [TBL] [Abstract][Full Text] [Related]
22. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762 [TBL] [Abstract][Full Text] [Related]
24. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659 [TBL] [Abstract][Full Text] [Related]
25. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343 [TBL] [Abstract][Full Text] [Related]
26. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593 [TBL] [Abstract][Full Text] [Related]
27. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W; Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102 [TBL] [Abstract][Full Text] [Related]
28. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma. Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992 [TBL] [Abstract][Full Text] [Related]
30. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102 [TBL] [Abstract][Full Text] [Related]
31. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. Zhao H; Wang S; Song C; Zha Y; Li L World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166 [TBL] [Abstract][Full Text] [Related]
32. Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. Brawanski KR; Sprung S; Freyschlag CF; Hoeftberger R; Ströbel T; Haybaeck J; Thomé C; Manzl C; Birkl-Toeglhofer AM Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047153 [TBL] [Abstract][Full Text] [Related]
33. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882 [TBL] [Abstract][Full Text] [Related]
34. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation. Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197 [TBL] [Abstract][Full Text] [Related]
35. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma. Lee A; Malakhov N; Sheth N; Wang A; Han P; Schreiber D Clin Neurol Neurosurg; 2018 Jul; 170():127-131. PubMed ID: 29777945 [TBL] [Abstract][Full Text] [Related]
36. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter. Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247 [TBL] [Abstract][Full Text] [Related]
37. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716 [TBL] [Abstract][Full Text] [Related]
38. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. Parkinson JF; Wheeler HR; Clarkson A; McKenzie CA; Biggs MT; Little NS; Cook RJ; Messina M; Robinson BG; McDonald KL J Neurooncol; 2008 Mar; 87(1):71-8. PubMed ID: 18004504 [TBL] [Abstract][Full Text] [Related]
40. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. Lee JY; Park CK; Park SH; Wang KC; Cho BK; Kim SK Childs Nerv Syst; 2011 Nov; 27(11):1877-83. PubMed ID: 21789683 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]